drugset / Trial / NCT03178643

Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)

NCT03178643 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

This is a randomized, three-arm, open-label, clinical trial of malaria chemoprevention in children with sickle-cell anemia (SCA) at a single site in Homa Bay, Kenya. The study will enroll 246 children under 10 years of age, randomize participants 1:1:1 to one of three malaria chemoprevention regimens, and follow participants monthly for 12 months in order to record clinical episodes of malaria or SCA-related morbidity. Analyses will compare the efficacy of each regimen to prevent malaria and SCA morbidity.

Timeline

Start
2018-01-23
Primary completion
2020-12-16
Completion
2020-12-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARTENIMOL Small molecule 10 mg —
Comparator ARTENIMOL Small molecule 20 mg —
Comparator ARTENIMOL Small molecule 30 mg —
Comparator ARTENIMOL Small molecule 40 mg —
Comparator ARTENIMOL Small molecule 50 mg —
Comparator ARTENIMOL Small molecule 60 mg —
Comparator Proguanil Small molecule 3 mg/kg Oral
Comparator amodiaquine Other / unclassified 153 mg —
Comparator amodiaquine Other / unclassified 229.5 mg —
Comparator piperaquine Small molecule 80 mg —
Comparator piperaquine Small molecule 160 mg —
Comparator piperaquine Small molecule 240 mg —
Comparator piperaquine Small molecule 320 mg —
Comparator piperaquine Small molecule 400 mg —
Comparator piperaquine Small molecule 480 mg —
Comparator pyrimethamine Small molecule 25 mg —
Comparator pyrimethamine Small molecule 37.5 mg —
Comparator sulfadoxine Small molecule 500 mg —
Comparator sulfadoxine Small molecule 750 mg —